Synopsis: Neogen Chemical compounds reported its This fall and full-year FY26 audited outcomes on Might 16, 2026, exhibiting stable standalone income development and a restoration in profitability. Nevertheless, the highlight is on subsidiary Neogen Ionics Restricted, whose Dahej and Pakhajan initiatives face revised timelines and swelling prices, elevating recent investor questions.
Neogen Chemical compounds Restricted held its Board of Administrators assembly on Saturday, Might 16, 2026, approving the standalone and consolidated audited monetary outcomes for This fall and the complete monetary yr ended March 31, 2026. The statutory auditors, M/s. Chandabhoy & Jassoobhoy, Chartered Accountants, issued an unmodified opinion on each the standalone and consolidated outcomes, offering clear regulatory compliance.
On the standalone entrance, Neogen delivered a robust income efficiency. Income from operations for FY26 stood at Rs. 855.49 crore, in comparison with Rs. 773.65 crore in FY25, reflecting a year-on-year development of roughly 10.6%. For This fall FY26 alone, income got here in at Rs. 248.63 crore in opposition to Rs. 203.75 crore in This fall FY25, a quarterly development of over 22%. Whole earnings for the complete yr reached Rs. 871.31 crore.
Web revenue for FY26 stood at Rs. 46.96 crore, barely decrease than Rs. 48.41 crore in FY25. The marginal dip in profitability was primarily attributed to a major bounce in finance prices, which practically doubled to Rs. 80.42 crore in FY26 from Rs. 51.38 crore in FY25, reflecting the corporate’s aggressive capital deployment into its subsidiary Neogen Ionics Restricted. Regardless of this, the working margin for FY26 got here in at a wholesome 17.68%, and the web revenue margin was 5.49%.
On the consolidated stage, the numbers paint a extra sobering image. Consolidated income from operations for FY26 reached Rs. 861.96 crore, with internet revenue attributable to the group at Rs. 28.75 crore, a major decline in comparison with the standalone determine, indicating significant losses on the subsidiary stage. The three subsidiary corporations collectively reported a internet lack of Rs. 18.31 crore for FY26, largely pushed by pre-revenue expenditure at Neogen Ionics.
Probably the most market-moving disclosure within the board consequence was the revision of challenge timelines and prices for Neogen Ionics Restricted (NIL), the corporate’s wholly-owned subsidiary targeted on battery chemical substances, a high-conviction wager on India’s EV and vitality storage provide chain.
The Dahej Part 1 challenge, initially slated for an earlier commissioning, now has a revised projected value of Rs. 428 crore with a Scheduled Industrial Operation Date (SCOD) of February 2027. The Pakhajan Part 2 challenge has been revised to Rs. 1,367 crore with a SCOD of March 2027, bringing the mixed capex to a staggering Rs. 1,795 crore. The corporate cited “design optimization based mostly on changeover from in-house to Japanese expertise” as the important thing purpose for value and timeline revisions. Encouragingly, the corporate acknowledged that an fairness infusion from a Promoter Group member has already been acquired, with extra funding from the JV associate deliberate.
Including to the monetary complexity, Neogen Chemical compounds additionally disclosed that the insurance coverage declare course of stemming from the devastating hearth at its Dahej SEZ plant on March 5, 2025 stays ongoing. Whereas Rs. 140 crore has been acquired as an on-account fee and Rs. 7.05 crore realized from scrap gross sales, the excellent insurance coverage declare receivable as of March 31, 2026 stands at Rs. 188.96 crore, a considerable determine administration believes is absolutely recoverable. The Board additionally beneficial a remaining dividend of Rs. 1 per fairness share for FY26, topic to shareholder approval on the upcoming thirty seventh AGM.
Shares of Neogen Chemical compounds Restricted have been buying and selling at Rs. 1,655.70 on Might 18, 2026, down 0.55% from the earlier shut of Rs. 1,664.80. The inventory opened at Rs. 1,690 and touched an intraday excessive of Rs. 1,695 and a low of Rs. 1,647. The corporate at present has a market capitalization of about Rs. 4,371 crore and trades at a excessive P/E of 154.32. The inventory is a part of the ASM-1 surveillance checklist and is included within the NIFTY Microcap 250 index.
Firm Overview
Neogen Chemical compounds Restricted is a Thane-based specialty chemical substances producer, primarily serving the pharmaceutical and agrochemical industries by way of its organolithium and bromine-based chemistry platforms. By its wholly-owned subsidiary Neogen Ionics Restricted, the corporate is making a strategic push into battery-grade lithium chemical substances, positioning itself as a key home provider for India’s fast-growing EV ecosystem.
Disclaimer: The views and funding ideas expressed by funding specialists/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the creator will not be accountable for any losses precipitated on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
